José María Fernandez-Gómez

José María Fernandez-Gómez

Auto-generated profile, based on publicly available information

José María Fernandez-Gómez

Department of Cell Biology, Genetics, Histology and Pharmacology, Faculty of Medicine, University of Valladolid, 47003 Valladolid, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Ricardo Usategui-MartínRicardo Usategui-Martín
Ricardo Usategui-Martín
NGNadia Galindo-Cabello
Nadia Galindo-Cabello
Salvador Pastor-IdoateSalvador Pastor-Idoate
Salvador Pastor-Idoate
JFJosé María Fernández-Gómez
José María Fernández-Gómez
ARAlvaro del Real
Alvaro del Real
JPJose-Luis Pérez-Castrillón
Jose-Luis Pérez-Castrillón
Metabolic bone diseases cover a broad spectrum of disorders that share alterations in bone metabolism that lead to a defective skeleton, which is associated with increasing morbidity, disability, and mortality. There is a close connection between the etiology of metabolic bone diseases and genetic factors, with TP53 being one of the genes associated therewith. The single nucleotide polymorphism (SNP) Arg72Pro of TP53 is a genetic factor associated with several pathologies, including cancer, stroke, and osteoporosis. Here, we aim to analyze the influence of the TP53 Arg72Pro SNP on bone mass in humanized Tp53 Arg72Pro knock-in mice. This work reports on the influence of the TP53 Arg72Pro polymorphism in bone microarchitecture, OPG expression, and apoptosis bone status. The results show that the proline variant of the TP53 Arg72Pro polymorphism (Pro72-p53) is associated with deteriorated bone tissue, lower OPG/RANK ratio, and lower apoptosis in bone tissue. In conclusion, the TP53 Arg72Pro polymorphism modulates bone microarchitecture and may be a genetic biomarker that can be used to identify individuals with an increased risk of suffering metabolic bone alterations.

10 October 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
Ricardo Usategui-MartínRicardo Usategui-Martín
Ricardo Usategui-Martín
NGNadia Galindo-Cabello
Nadia Galindo-Cabello
Salvador Pastor-IdoateSalvador Pastor-Idoate
Salvador Pastor-Idoate
JFJosé María Fernandez-Gómez
José María Fernandez-Gómez
ARAlvaro del Real
Alvaro del Real
JPJose-Luis Pérez-Castrillón
Jose-Luis Pérez-Castrillón
Metabolic bone diseases cover a broad spectrum of disorders that share alterations of bone metabolism leading to a defective skeleton, associated with increasing morbidity, disability, and mortality. There is a close connection between the etiology of metabolic bone diseases and genetic factors, being TP53 one of the genes associated therewith. The single nucleotide polymorphism (SNP) Arg72Pro of TP53 is a genetic factor associated with several pathologies, including cancer, stroke and osteoporosis. Here, we aim to analyze the influence of the TP53 Arg72Pro SNP on bone mass in the humanized Tp53 Arg72Pro knock-in mice. This work reported on the influence of TP53 Arg72Pro polymorphism in bone microarchitecture, OPG gene expression and apoptosis bone status. The results showed that the proline variant of TP53 Arg72Pro polymorphism (Pro72-p53) was associated with deteriorated bone tissue, lower OPG/RANK ratio and lower apoptosis in bone tissue. In conclusion, the TP53 Arg72Pro polymorphism modulates bone microarchitecture and may be a genetic biomarker to identify individuals with an increased risk of suffering metabolic bone alterations